AMD Pharmacogenetics

Vita Risk Pharmacogenetic Result

The Vita Risk pharmacogenetic result within the Macula Risk PGx test is intended to support the genotype-directed selection of appropriate eye supplement formulations. The eye supplement formulation (AREDS, or AREDS without zinc) shown to result in the greatest reduction in the risk of progression to advanced AMD for the patient’s combined CFH/ARMS2 genotype is recommended [5].

The Vita Risk pharmacogenetic result is covered by published pending US Patent application number: 13/955502 and CA2,914,722.
Macula Risk PGx is covered by patent applications including WIPO Patent Nos. 2009029587 and 2011006161; United States Patent Nos. 20100304369A and 12382569; and pending published patent applications WO 2009146204; WO 2007120975; WO2010111595; WO2011006161 & unpublished applications.

The Vita Risk Patient Report is shown below: